<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169215">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893971</url>
  </required_header>
  <id_info>
    <org_study_id>PT0030901</org_study_id>
    <nct_id>NCT00893971</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Single Dose, Four-period, Four-treatment, Cross-over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of a single dose of PT003 compared with
      single doses of PT001 and PT005, and compared with PT001 plus PT005 delivered together as
      two separate single doses in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of PT003 compared with PT001 and PT005, and compared with PT001 + PT005 delivered together in two separate inhalers</measure>
    <time_frame>12-hours following study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PT003, PT001 and PT005 and PT001 + PT005 from separate inhalers</measure>
    <time_frame>Immediately prior to study drug administration and at 2, 5, 10, 15, 30 minutes as well as 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 18 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT005 2.4 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 18 μg + PT005 2.4 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001</intervention_name>
    <description>Inhaled PT001, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005</intervention_name>
    <description>Inhaled PT005, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003</intervention_name>
    <description>Inhaled PT003, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 + PT005</intervention_name>
    <description>Inhaled PT001 + PT005, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed written informed consent

          -  18-55 years of age

          -  Healthy subjects confirmed by medical history, physical examination, vital signs,
             pulmonary function tests, electrocardiogram and clinical laboratory tests

          -  Female subjects of child-bearing potential who are sexually active must be willing to
             undergo a pregnancy test and agree to use two forms of contraception

          -  Body mass index (BMI) between 18.5 and 30, inclusive

          -  Non-smokers for at least 6 months prior to screening

          -  Pulmonary function tests within normal limits

          -  Willing to remain at the study center for at least 12-24 hours on each test day

          -  Venous access in both arms to allow collection of numerous blood samples

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Clinically significant medical conditions

          -  Viral illness within the last 30 days

          -  Symptomatic prostatic hypertrophy or bladder neck obstruction

          -  Known narrow-angle glaucoma

          -  History of bowel obstruction

          -  Clinically significant abnormal electrocardiogram

          -  Positive Hepatitis B surface antigen or positive Hepatitis C antibody

          -  Positive screening test for HIV antibodies

          -  History of hypersensitivity to any beta2-agonists, anticholinergics, or any component
             of the MDI

          -  Known or suspected history of alcohol or drug abuse within the last 2-years

          -  Greater than normal alcohol consumption

          -  Ingestion of any poppy seeds within the 48 hours prior to the screening

          -  Ingestion of any poppy seeds within the 48 hours prior to, or any alcohol, xanthines
             or grapefruit-containing foods or beverages within the 24 hours prior to, or during,
             each confinement

          -  Positive breath alcohol result

          -  Positive urine drug screen

          -  Use of any beta2-agonists,or anticholinergics prior to the recruitment interview

          -  Lower respiratory tract infections requiring antibiotics in the previous 6 weeks

          -  Use of any other prescription medication

          -  Use of any over the counter product, herbal product, diet aid, hormone supplement

          -  Donation &gt; 450 ml of blood within 8 weeks of first treatment dose

          -  Clinically significant vital sign abnormality

          -  Clinically significant biochemical, hematological or urinalysis abnormality

          -  Affiliations with investigator site

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives prior to screening, whichever is
             longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Joanne Marjason</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 13, 2010</lastchanged_date>
  <firstreceived_date>May 5, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Colin Reisner, M.D./Chief Medical Officer</name_title>
    <organization>Pearl Therapeutics, Inc</organization>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
